Despite the many advances in oncology, important problems continue to beset the field, including rapidly rising costs, uneven patterns of care, and poor access to (and participation in) cancer trials. A model that has been recently developed and tested to address these issues is the so-called academic hybrid community cancer center.
As a cancer patient advocacy organization—especially one dedicated to a category of malignancies that have seen frustratingly slow progress and only negligible improvements in survival rates over the past four-plus decades—we've come to view our role and responsibility to the brain tumor community as something like that of a plumber.
Systemic therapies for metastatic renal cell carcinoma (mRCC) have expanded dramatically over the past 3 years.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers.
The Hokusai-VTE CANCER study evaluating oral edoxaban (known as Savaysa in the U.S. and Lixiana outside the U.S.) found edoxaban to be non-inferior to subcutaneous injectable LMWH dalteparin for the treatment of cancer-associated VTE or major bleeding.
Patients with early stage lung cancer live longer when they receive a lobectomy rather than a less extensive operation or radiation treatment, according to a study published in The Annals of Thoracic Surgery.
A phase IIb clinical trial for Galera Therapeutics' GC4419 met its primary endpoint, demonstrating a significant (p=0.024), clinically meaningful and dose-dependent reduction in the duration of severe oral mucositis in patients with head and neck cancer receiving chemoradiation.
A pivotal phase II clinical study of cemiplimab, an investigational human antibody targeting PD-1, demonstrated an overall response rate of 46.3% in 82 patients with advanced cutaneous squamous cell carcinoma.
Genentech's phase III IMmotion151 study met its co-primary endpoint ofprogression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death in people whose disease expressed the PD-L1 (PD-L1 expression ≥1 percent) protein compared with sunitinib for the first-line treatment of people who have advanced or metastatic renal cell carcinoma.
